Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 496

1.

Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again.

Bucktrout SL, Bluestone JA, Ramsdell F.

Genome Med. 2018 Oct 31;10(1):79. doi: 10.1186/s13073-018-0588-4.

2.

Regulatory T cell therapy for autoimmune and autoinflammatory diseases: the next frontier.

Esensten JH, Muller YD, Bluestone JA, Tang Q.

J Allergy Clin Immunol. 2018 Oct 24. pii: S0091-6749(18)31484-2. doi: 10.1016/j.jaci.2018.10.015. [Epub ahead of print]

PMID:
30367909
3.

Treg cells-the next frontier of cell therapy.

Bluestone JA, Tang Q.

Science. 2018 Oct 12;362(6411):154-155. doi: 10.1126/science.aau2688. No abstract available.

PMID:
30309932
4.

Adoptive Regulatory T Cell Therapy in a Patient with Systemic Lupus Erythematosus.

Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandoval PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD; Autoimmunity Centers of Excellence.

Arthritis Rheumatol. 2018 Oct 1. doi: 10.1002/art.40737. [Epub ahead of print]

PMID:
30277008
5.

Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy.

Spangler JB, Trotta E, Tomala J, Peck A, Young TA, Savvides CS, Silveria S, Votavova P, Salafsky J, Pande VS, Kovar M, Bluestone JA, Garcia KC.

J Immunol. 2018 Oct 1;201(7):2094-2106. doi: 10.4049/jimmunol.1800578. Epub 2018 Aug 13.

PMID:
30104245
6.

Chance favours the prepared mind.

Bluestone JA.

Nat Rev Immunol. 2018 Sep;18(9):541. doi: 10.1038/s41577-018-0043-1. No abstract available.

7.

Revisiting IL-2: Biology and therapeutic prospects.

Abbas AK, Trotta E, R Simeonov D, Marson A, Bluestone JA.

Sci Immunol. 2018 Jul 6;3(25). pii: eaat1482. doi: 10.1126/sciimmunol.aat1482. Review.

PMID:
29980618
8.

A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism.

Trotta E, Bessette PH, Silveria SL, Ely LK, Jude KM, Le DT, Holst CR, Coyle A, Potempa M, Lanier LL, Garcia KC, Crellin NK, Rondon IJ, Bluestone JA.

Nat Med. 2018 Jul;24(7):1005-1014. doi: 10.1038/s41591-018-0070-2. Epub 2018 Jun 25.

9.

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC.

Diabetes. 2018 Aug;67(8):1471-1480. doi: 10.2337/dbi18-0002. Epub 2018 Jun 24. Review.

10.

Author Correction: Discovery of stimulation-responsive immune enhancers with CRISPR activation.

Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, Woo JM, Mitros T, Ray GJ, Curie GL, Naddaf N, Chu JS, Ma H, Boyer E, Van Gool F, Huang H, Liu R, Tobin VR, Schumann K, Daly MJ, Farh KK, Ansel KM, Ye CJ, Greenleaf WJ, Anderson MS, Bluestone JA, Chang HY, Corn JE, Marson A.

Nature. 2018 Jul;559(7715):E13. doi: 10.1038/s41586-018-0227-7.

PMID:
29899441
11.

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.

Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M.

Cell Rep. 2018 Jun 12;23(11):3262-3274. doi: 10.1016/j.celrep.2018.05.050.

12.

Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges.

Sneddon JB, Tang Q, Stock P, Bluestone JA, Roy S, Desai T, Hebrok M.

Cell Stem Cell. 2018 Jun 1;22(6):810-823. doi: 10.1016/j.stem.2018.05.016. Review.

PMID:
29859172
13.

Pathological conversion of regulatory T cells is associated with loss of allotolerance.

Hua J, Inomata T, Chen Y, Foulsham W, Stevenson W, Shiang T, Bluestone JA, Dana R.

Sci Rep. 2018 May 4;8(1):7059. doi: 10.1038/s41598-018-25384-x.

14.

Revealing the specificity of regulatory T cells in murine autoimmune diabetes.

Spence A, Purtha W, Tam J, Dong S, Kim Y, Ju CH, Sterling T, Nakayama M, Robinson WH, Bluestone JA, Anderson MS, Tang Q.

Proc Natl Acad Sci U S A. 2018 May 15;115(20):5265-5270. doi: 10.1073/pnas.1715590115. Epub 2018 Apr 30. Erratum in: Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):E5634.

15.

Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes.

Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, Ribas A, Bluestone JA, Garcia KC.

Science. 2018 Mar 2;359(6379):1037-1042. doi: 10.1126/science.aar3246.

16.

Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.

Fuchs A, Gliwiński M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Gołab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grześ D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P.

Front Immunol. 2018 Jan 15;8:1844. doi: 10.3389/fimmu.2017.01844. eCollection 2017.

17.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A.

Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Review.

18.

Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes.

Yeh WI, Seay HR, Newby B, Posgai AL, Moniz FB, Michels A, Mathews CE, Bluestone JA, Brusko TM.

Front Immunol. 2017 Oct 26;8:1313. doi: 10.3389/fimmu.2017.01313. eCollection 2017.

19.

Discovery of stimulation-responsive immune enhancers with CRISPR activation.

Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, Woo JM, Mitros T, Ray GJ, Curie GL, Naddaf N, Chu JS, Ma H, Boyer E, Van Gool F, Huang H, Liu R, Tobin VR, Schumann K, Daly MJ, Farh KK, Ansel KM, Ye CJ, Greenleaf WJ, Anderson MS, Bluestone JA, Chang HY, Corn JE, Marson A.

Nature. 2017 Sep 7;549(7670):111-115. doi: 10.1038/nature23875. Epub 2017 Aug 30. Erratum in: Nature. 2018 Jul;559(7715):E13.

20.

Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy?

June CH, Warshauer JT, Bluestone JA.

Nat Med. 2017 Aug 4;23(8):1004. doi: 10.1038/nm0817-1004b. No abstract available.

PMID:
28777789
21.

Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants.

Chandran S, Tang Q, Sarwal M, Laszik ZG, Putnam AL, Lee K, Leung J, Nguyen V, Sigdel T, Tavares EC, Yang JYC, Hellerstein M, Fitch M, Bluestone JA, Vincenti F.

Am J Transplant. 2017 Nov;17(11):2945-2954. doi: 10.1111/ajt.14415. Epub 2017 Aug 14.

22.

Is autoimmunity the Achilles' heel of cancer immunotherapy?

June CH, Warshauer JT, Bluestone JA.

Nat Med. 2017 May 5;23(5):540-547. doi: 10.1038/nm.4321. Erratum in: Nat Med. 2017 Aug 4;23 (8):1004.

23.

Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes.

Morita S, Villalta SA, Feldman HC, Register AC, Rosenthal W, Hoffmann-Petersen IT, Mehdizadeh M, Ghosh R, Wang L, Colon-Negron K, Meza-Acevedo R, Backes BJ, Maly DJ, Bluestone JA, Papa FR.

Cell Metab. 2017 May 2;25(5):1207. doi: 10.1016/j.cmet.2017.04.026. No abstract available.

24.

Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes.

Morita S, Villalta SA, Feldman HC, Register AC, Rosenthal W, Hoffmann-Petersen IT, Mehdizadeh M, Ghosh R, Wang L, Colon-Negron K, Meza-Acevedo R, Backes BJ, Maly DJ, Bluestone JA, Papa FR.

Cell Metab. 2017 Apr 4;25(4):883-897.e8. doi: 10.1016/j.cmet.2017.03.018. Erratum in: Cell Metab. 2017 May 2;25(5):1207.

25.

Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy.

Seay HR, Putnam AL, Cserny J, Posgai AL, Rosenau EH, Wingard JR, Girard KF, Kraus M, Lares AP, Brown HL, Brown KS, Balavage KT, Peters LD, Bushdorf AN, Atkinson MA, Bluestone JA, Haller MJ, Brusko TM.

Mol Ther Methods Clin Dev. 2016 Dec 24;4:178-191. doi: 10.1016/j.omtm.2016.12.003. eCollection 2017 Mar 17.

26.

FOXP3, the Transcription Factor at the Heart of the Rebirth of Immune Tolerance.

Bluestone JA.

J Immunol. 2017 Feb 1;198(3):979-980. doi: 10.4049/jimmunol.1602060. No abstract available.

27.

Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials.

Esensten JH, Bluestone JA, Lim WA.

Annu Rev Pathol. 2017 Jan 24;12:305-330. doi: 10.1146/annurev-pathol-052016-100304. Epub 2016 Dec 5. Review.

28.

CD28 Costimulation: From Mechanism to Therapy.

Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA.

Immunity. 2016 May 17;44(5):973-88. doi: 10.1016/j.immuni.2016.04.020. Review.

29.

Correction: CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis.

Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF.

J Immunol. 2016 May 1;196(9):3966. doi: 10.4049/jimmunol.1600364. No abstract available.

30.

Regulatory T cell therapy for type 1 diabetes: May the force be with you.

Gitelman SE, Bluestone JA.

J Autoimmun. 2016 Jul;71:78-87. doi: 10.1016/j.jaut.2016.03.011. Epub 2016 Apr 28. Review.

PMID:
27133597
31.

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.

Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR; ITN START Study Team.

Diabetologia. 2016 Jun;59(6):1153-61. doi: 10.1007/s00125-016-3917-4. Epub 2016 Apr 6.

32.

Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.

DuPage M, Bluestone JA.

Nat Rev Immunol. 2016 Mar;16(3):149-63. doi: 10.1038/nri.2015.18. Epub 2016 Feb 15. Review.

33.

Inducing and Administering Tregs to Treat Human Disease.

Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC.

Front Immunol. 2016 Jan 22;6:654. doi: 10.3389/fimmu.2015.00654. eCollection 2015. Review.

34.

CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis.

Roan F, Stoklasek TA, Whalen E, Molitor JA, Bluestone JA, Buckner JH, Ziegler SF.

J Immunol. 2016 Mar 1;196(5):2051-2062. doi: 10.4049/jimmunol.1501491. Epub 2016 Jan 29. Erratum in: J Immunol. 2016 May 1;196(9):3966.

35.

Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q.

Sci Transl Med. 2015 Nov 25;7(315):315ra189. doi: 10.1126/scitranslmed.aad4134.

36.

Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.

Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, Bluestone JA, Burton BK, Dewey M, Freitas A, Gavin D, Griebel D, Hogan M, Holland S, Tanpaiboon P, Turka LA, Utz JJ, Wang YM, Whitley CB, Kazi ZB, Pariser AR.

Mol Genet Metab. 2016 Feb;117(2):66-83. doi: 10.1016/j.ymgme.2015.11.001. Epub 2015 Nov 10. Review.

PMID:
26597321
37.

The immune system in Duchenne muscular dystrophy: Friend or foe.

Villalta SA, Rosenberg AS, Bluestone JA.

Rare Dis. 2015 Feb 23;3(1):e1010966. doi: 10.1080/21675511.2015.1010966. eCollection 2015.

38.

Shifting the Evolving CAR T Cell Platform into Higher Gear.

Holohan DR, Lee JC, Bluestone JA.

Cancer Cell. 2015 Oct 12;28(4):401-402. doi: 10.1016/j.ccell.2015.09.014.

39.

Targeting Treg signaling for the treatment of autoimmune diseases.

Spence A, Klementowicz JE, Bluestone JA, Tang Q.

Curr Opin Immunol. 2015 Dec;37:11-20. doi: 10.1016/j.coi.2015.09.002. Epub 2015 Sep 29. Review.

40.

Generation of knock-in primary human T cells using Cas9 ribonucleoproteins.

Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, Haliburton GE, Ye CJ, Bluestone JA, Doudna JA, Marson A.

Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10437-42. doi: 10.1073/pnas.1512503112. Epub 2015 Jul 27.

41.

Interleukin-33 and Interferon-γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation.

Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, Bluestone JA, Locksley RM.

Immunity. 2015 Jul 21;43(1):161-74. doi: 10.1016/j.immuni.2015.05.019. Epub 2015 Jun 16.

42.

Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.

Fuhrman CA, Yeh WI, Seay HR, Saikumar Lakshmi P, Chopra G, Zhang L, Perry DJ, McClymont SA, Yadav M, Lopez MC, Baker HV, Zhang Y, Li Y, Whitley M, von Schack D, Atkinson MA, Bluestone JA, Brusko TM.

J Immunol. 2015 Jul 1;195(1):145-55. doi: 10.4049/jimmunol.1402381. Epub 2015 May 20.

43.

IL-2: Change Structure … Change Function.

Bluestone JA, Crellin N, Trotta E.

Immunity. 2015 May 19;42(5):779-81. doi: 10.1016/j.immuni.2015.05.002.

44.

T cells in the control of organ-specific autoimmunity.

Bluestone JA, Bour-Jordan H, Cheng M, Anderson M.

J Clin Invest. 2015 Jun;125(6):2250-60. doi: 10.1172/JCI78089. Epub 2015 May 18. Review.

45.

The therapeutic potential of regulatory T cells for the treatment of autoimmune disease.

Bluestone JA, Trotta E, Xu D.

Expert Opin Ther Targets. 2015;19(8):1091-103. doi: 10.1517/14728222.2015.1037282. Epub 2015 Apr 16. Review.

46.

Immunotherapy: making the case for precision medicine.

Bluestone JA, Tang Q.

Sci Transl Med. 2015 Mar 25;7(280):280ed3. doi: 10.1126/scitranslmed.aaa9846. No abstract available.

47.

The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation.

DuPage M, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, Zhang R, Turka L, Marson A, Bluestone JA.

Immunity. 2015 Feb 17;42(2):227-238. doi: 10.1016/j.immuni.2015.01.007. Epub 2015 Feb 10.

48.

Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability.

Huynh A, DuPage M, Priyadharshini B, Sage PT, Quiros J, Borges CM, Townamchai N, Gerriets VA, Rathmell JC, Sharpe AH, Bluestone JA, Turka LA.

Nat Immunol. 2015 Feb;16(2):188-96. doi: 10.1038/ni.3077. Epub 2015 Jan 5.

49.

Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm.

Szot GL, Yadav M, Lang J, Kroon E, Kerr J, Kadoya K, Brandon EP, Baetge EE, Bour-Jordan H, Bluestone JA.

Cell Stem Cell. 2015 Feb 5;16(2):148-57. doi: 10.1016/j.stem.2014.12.001. Epub 2014 Dec 18.

50.

Innate antiviral host defense attenuates TGF-β function through IRF3-mediated suppression of Smad signaling.

Xu P, Bailey-Bucktrout S, Xi Y, Xu D, Du D, Zhang Q, Xiang W, Liu J, Melton A, Sheppard D, Chapman HA, Bluestone JA, Derynck R.

Mol Cell. 2014 Dec 18;56(6):723-37. doi: 10.1016/j.molcel.2014.11.027.

Supplemental Content

Loading ...
Support Center